BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Assessment of the Effectiveness of IV and SC Abatacept (Orencia) Patient Alert Cards in Patients With Rheumatoid Arthritis in a Sample of EU Countries

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2015-12-17

Last Posted Date: 2017-06-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 203

Registration Number: NCT02632890

Locations: 🇩🇪
Heidelberg, Heidelberg, Germany
🇬🇧
Local Institution, Harlow, United Kingdom
🇩🇪
Bad Nauheim, Bad Nauheim, Germany

and more 22 locations

An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer

Phase 3

Active, not recruiting

Conditions: Various Advanced Cancer

Interventions: Biological: Nivolumab
Other: Placebo

First Posted Date: 2015-12-16

Last Posted Date: 2024-01-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 709

Registration Number: NCT02632409

Locations: 🇮🇹
Local Institution - 0084, Pisa, Italy
🇺🇸
Local Institution - 0074, Allentown, Pennsylvania, United States
🇬🇧
Local Institution - 0036, London, United Kingdom

and more 184 locations

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Phase 3

Completed

Conditions: Brain Cancer

Interventions: Drug: Nivolumab
Drug: Temozolomide
Radiation: Radiotherapy

First Posted Date: 2015-12-01

Last Posted Date: 2023-03-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 560

Registration Number: NCT02617589

Locations: 🇺🇸
Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0090, Chattanooga, Tennessee, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 112 locations

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Nivolumab

First Posted Date: 2015-11-24

Last Posted Date: 2021-07-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 74

Registration Number: NCT02612779

Locations: 🇺🇸
Bay Hematology Oncology, Easton, Maryland, United States
🇺🇸
Southern Cancer Center, Mobile, Alabama, United States
🇺🇸
Virginia Cancer Specialists (Leesburg) - USOR, Leesburg, Virginia, United States

and more 19 locations

Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Nivolumab
Drug: Docetaxel

First Posted Date: 2015-11-24

Last Posted Date: 2024-11-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 504

Registration Number: NCT02613507

Locations: 🇨🇳
Local Institution - 0051, Beijing, Beijing, China
🇨🇳
Local Institution - 0007, Beijing, Beijing, China
🇷🇺
Local Institution - 0039, Chelyabinsk, Russian Federation

and more 30 locations

Safety and Tolerability Study of BMS-986177 in Healthy Subjects

Phase 1

Completed

Conditions: Thrombosis

Interventions: Other: Placebo
Drug: BMS-986177

First Posted Date: 2015-11-20

Last Posted Date: 2017-07-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 104

Registration Number: NCT02608970

Locations: 🇧🇪
SGS Belgium NV, Antwerpen, Belgium

Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Orencia

First Posted Date: 2015-11-09

Last Posted Date: 2017-01-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 505

Registration Number: NCT02600455

Locations: 🇯🇵
Local Institution, Shinjuku-ku, Tokyo, Japan

Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Orencia

First Posted Date: 2015-11-09

Last Posted Date: 2017-01-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 671

Registration Number: NCT02600468

An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: BMS-986156
Drug: Nivolumab

First Posted Date: 2015-11-06

Last Posted Date: 2023-03-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 295

Registration Number: NCT02598960

Locations: 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

and more 14 locations

Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma

Phase 3

Completed

Conditions: Melanoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2015-11-06

Last Posted Date: 2021-06-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 533

Registration Number: NCT02599402

Locations: 🇬🇧
Mount Vernon Hospital, Northwood, United Kingdom
🇬🇧
Local Institution, Truro, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy